While other treatment strategies most often come into play, diet and exercise are the principal staples in the fight against weight gain and obesity. The role of proper nutrition in maintaining a ...

Metformin may reduce knee pain in overweight patients with osteoarthritis, offering a low-cost alternative to early knee ...

Two in three adults could be obese by 2050, according to world heart report (EMB Sat 17th 00:00) - More than 800 million ...

Mexico's type 2 diabetes crisis, with a prevalence of 16·9%, has made the country a focal point for fiscal policies targeting ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.

The $7.8 million investment will fund further drug testing and development to advance its drug candidates to clinical trials.

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...